Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Diabetic Macular Edema Market: Revenues Estimated to Climb Modestly at a CAGR of 3.2% During the Study Period 2018-2030 in the 7MM, Foresees DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

10 May, 2021, 17:30 GMT

Share this article

Share toX

Share this article

Share toX

An increase in diabetes cases, entry of therapies having similar efficacy and safety to the current standard of care with the less frequent requirement of injections, better screening and personalized treatment are driving the market growth

LAS VEGAS, May 10, 2021 /PRNewswire/ -- DelveInsight's Diabetic Macular Edema (DME) Market report offers detailed information on current treatment practices, emerging drugs, Diabetic Macular Edema market share of the individual therapies, current and forecasted Diabetic Macular Edema market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Key highlights from the Diabetic Macular Edema Market Report

  • The total Diabetic Macular Edema prevalent population in the 7MM was 1,862,529 in 2020. The United States accounted for the maximum DME prevalent cases, while France reported the least.
  • The DME prevalence shall further rise owing to an increase in the ageing population and a shift towards the sedentary lifestyle of the people.
  • The present Diabetic Macular Edema therapeutic market is primarily dominated by Anti-VEGF therapies (Eylea, Lucentis and off-label Avastin) as the first-line defense treatment for DME. 
  • Due to low price and comparable efficacy to Eylea and Lucentis, the majority of physicians still prefer Avastin (bevacizumab) as an off-label therapy. In the US, currently, around 50% of DME patients are treated with first-line off-label Avastin.
  • Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye. 
  • DelveInsight predicts that prolonged ocular half-life therapies with fewer average injections per year, as well as other effective, safe, and innovative approaches are bound to embrace the DME market domain. 
  • Key DME pipeline therapies expected to enter the market during the forecast period 2021-30 include ADVM-022, GB-102, Faricimab (RG 7716), Beovu (RTH258; brolucizumab), KVD001, APX3330, THR-149, YD-312, LKA651, Abicipar, Luminate (ALG-1001, Risuteganib), KSI-301, Xipere (CLS-TA), among several others. 
  • Around in one-quarter or more of eyes with centre-involving DME do not achieve complete resolution of the edema with current anti-VEGF therapy and currently, there are no curative treatment options for this refractory pool. 

Download report to understand which drug is going to capture the maximum market share @ Diabetic Macular Edema Market Analysis and Forecast 

Diabetic Macular Edema is a build-up of fluid in the macula part of the retina due to leaking blood vessels. It is triggered by Diabetic Retinopathy, a complication of Diabetes. 

DME affects slightly more males as compared to females. As per DelveInsight's Diabetic Macular Edema epidemiological analysis, the United States accounted for the highest DME prevalent cases, nearly 55% of the total 7MM cases in 2020.

Diabetic Macular Edema Epidemiology

Diabetic Macular Edema Market Insights Report offers historical as well as forecasted epidemiological analysis segmented into during the study period 2018-30 in the 7MM:

  • Total DME Prevalent Cases
  • Total Diagnosed Prevalent Cases 
  • Gender-specific Diagnosed DME Prevalent Cases 
  • Age-specific Diagnosed Diabetic Macular Edema Prevalent Cases
  • Subgroups-Specific DME Edema Prevalent Cases
  • Diabetic Macular Edema Treated Cases

Visit for deep insights into DME patient pool @ Diabetic Macular Edema Epidemiology 

Diabetic Macular Edema Therapy Market 

The therapeutics market for Diabetic Macular Edema comprises Anti-VEGF therapies, namely Eylea and Lucentis, and Avastin as an Off-label therapy. These therapies work by inhibiting the activity of VEGF and improving visual acuity and anatomic results with a low risk of side effects. Besides, two US FDA-approved sustained-release corticosteroid implants for more serious or longer-lasting conditions, Ozurdex and Iluvien, are also available. Generally, Corticosteroid implants are used as a second-line treatment in cases where anti-VEGF injections fail to bring outputs. 

Unmet Needs in the Diabetic Macular Edema Therapeutics Market

At present, there are no curative treatment options in the Diabetic Macular Edema market. Approved Anti-VEGFs put a financial burden on patients; therefore, the DME market has witnessed an off-label use of Avastin (Roche/Genentech), which received approval for the treatment of neovascular AMD and expanded to cover venous occlusive diseases, neovascular glaucoma, choroidal neovascularization unrelated to ME, proliferative DR, and others.

As per the analysis from some studies, it is demonstrated that from 20% to 60% of total DME patients do not respond to Anti-VEGF therapies. Further, the available treatment options target only one pathway, despite the clarity of the multifactorial nature of DME. 

Underdiagnoses of the condition, due to the late onset of symptoms, is another major unmet need in the market that leads to a delay in treatment, thus, increasing the chances of permanent vision loss. 

Access the sample copy of the report for more details @ Diabetic Macular Edema Market Unmet Needs

Diabetic Macular Edema Market

DelveInsight's DME market analysis projects a robust pipeline activity consisting of promising emerging drug therapies. With a horde of companies including  Adverum Biotechnologies, Graybug Vision, Novartis, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, Allergan (AbbVie)/Molecular Partners, Allergo Ophthalmics/ Bausch Health, Kodiak Sciences, Clearside Biomedical, Roche, and others advancing the R&D, and developing innovative medicines, thereby, adding to the growth of DME market size. 

Late-stage pipeline drugs such as Faricimab, Beovu, and KSI-301 are the potential emerging therapies that have shown promising results and are expected to improve the dosing interval. 

Check out for more @ Diabetic Macular Edema Market Forecast 

Key Diabetic Macular Edema Pipeline Therapies and Companies

  • ADVM-022: Adverum Biotechnologies
  • GB-102: Graybug Vision
  • Faricimab (RG 7716): Roche
  • Beovu (RTH258; brolucizumab): Novartis
  • KVD001: KalVista Pharmaceuticals
  • APX3330: Ocuphire Pharma
  • THR-149: Oxurion
  • YD-312: YD Life Science
  • LKA651: Novartis
  • Abicipar: Allergan (AbbVie)/Molecular Partners
  • Luminate (ALG-1001, Risuteganib): Allergo Ophthalmics/ Bausch Health
  • KSI-301: Kodiak Sciences
  • Xipere (CLS-TA): Clearside Biomedical

Reach out to us @ Diabetic Macular Edema Marketed Therapies for more information on marketed DME treatment regimens 

Diabetic Macular Edema Market Drivers and Barriers 

Increasing patient pool of diabetes, personalization of treatment, new pathways and novel approaches are some of the factors, which will drive the DME market growth forward. Globally, the number of patients with diabetes increased from 177 million cases in 2000 to 285 million in 2010 and are estimated to be more than 360 million cases by 2030. With the Increasing prevalence of diabetes across, the number of patients suffering from DME is also expected to rise. 

Companies are also working on other novel therapies with novel MOAs, such as THR-149, targeting inhibition of the plasma kallikrein-kinin (PKaI-kinin) system and APX3330 having dual MOA.

In contrast, exorbitant cost, shortage of trained ophthalmologists, lack of awareness of eye conditions, underdiagnoses of DME, and entry of biosimilars are likely to hinder the DME market growth.

Scope of the Report 

Coverage: 7MM (the US, EU5, and Japan)

Study Period: 2018-30

Key Companies: Adverum Biotechnologies, Graybug Vision, Novartis, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, Allergan (AbbVie)/Molecular Partners, Allergo Ophthalmics/ Bausch Health, Kodiak Sciences, Clearside Biomedical, Roche, and others. 

Key Diabetic Macular Edema Pipeline Therapies: ADVM-022, GB-102, Faricimab (RG 7716), Beovu (RTH258; brolucizumab), KVD001, APX3330, THR-149, YD-312, LKA651, Abicipar, Luminate (ALG-1001, Risuteganib), KSI-301, Xipere (CLS-TA), and others. 

Diabetic Macular Edema Market Segmentation: By Geography, By Diabetic Macular Edema Therapies

Analysis: Comparative and conjoint analysis of Diabetic Macular Edema emerging therapies

Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL's Views

Analyst's Views

Drop by to learn more about the future market trends @ Diabetic Macular Edema Market Landscape and Forecast 

Table of Contents 

1

Key Insights

2

Diabetic Macular Edema Market Report Introduction

3

Diabetic Macular Edema Market Overview at a Glance

4

Executive Summary of Diabetic Macular Edema

5

Disease Background and Overview

6

Algorithm for Diagnosis of Diabetic Macular Edema 

7

Patient Journey

8

Diabetic Macular Edema (DME) Epidemiology and Patient Population

9

Treatment Algorithm, Current Treatment, and Medical Practices

10

Diabetic Macular Edema Epidemiology and Patient Population

11

Country Wise-Epidemiology of Diabetic Macular Edema

10

Diabetic Macular Edema Treatment 

12

Unmet Needs

13

Key Endpoints of Diabetic Macular Edema (DME) Treatment

14

Diabetic Macular Edema Emerging Therapies

15

Diabetic Macular Edema: 7 Major Market Analysis

16

Diabetic Macular Edema Market Unmet Needs 

17

Case Reports

18

Diabetic Macular Edema Market Drivers

19

Diabetic Macular Edema Market Barriers

20

SWOT Analysis

21

KOL Reviews

21

Appendix

22

DelveInsight Capabilities

23

Disclaimer

24

About DelveInsight

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

Related Reports 

Dementia With Diabetes Market Forecast

DelveInsight's 'Dementia with Diabetes—Market Insights, Epidemiology and Market Forecast–2030' report.

Diabetes Market

DelveInsight's "Diabetes Market Insights, Epidemiology, and Market Forecast-2030" report.

Gestational Diabetes Market

DelveInsight's "Gestational Diabetes - Market Insights, Epidemiology, and Market Forecast - 2030" report.

Type 1 Diabetes Market

DelveInsight's "Type 1 Diabetes - Market Insights, Epidemiology, and Market Forecast - 2030" report. 

Type 2 Diabetes Market

DelveInsight's "Type 2 Diabetes - Market Insights, Epidemiology, and Market Forecast-2030" report.

Diabetes Pen Market Market

DelveInsight's 'Diabetes Pen Market-Market Insights, Competitive Landscape and Market Forecast - 2026' report offers a detailed analysis of therapies and key pharmaceutical companies including AstraZeneca, Teruma Medical Corporation, Greinier Bio One International GmBH, F. Hoffman La Roche AG, Becton, Dickinson and Company Bayer Cropscience Ltd, and others.

Related Posts

Understanding The Increasing Prevalence Of Diabetes And Its Complications

Diabetic Peripheral Neuropathy Market Landscape 

Diabetic Peripheral Neuropathy Medications 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us

Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.